Immunotech Biopharm’s CAR-T-19-D2 Receives NMPA Approval for DLBCL Clinical Trial
China-based chimeric antigen receptor T-cell (CAR-T) specialist Immunotech Biopharm Ltd (HKG: 6978) has announced that...
Cancer
3SBio Inc. Reports 7.5% Revenue Growth in 2022 Financials
China-based 3SBio Inc. (HKG: 1530) released its 2022 financial report, recording revenues of RMB 6.859...
Jacobio Pharma Partners with Merck to Evaluate CD73 mAb and Keytruda Combination
China-based Jacobio Pharma (HKG: 1167) has announced a clinical partnership with Merck, Sharp & Dohme...
BioNTech Acquires Global Rights to OncoC4’s Anti-CTLA-4 Antibody ONC-392
Germany-based mRNA specialist BioNTech SE (NASDAQ: BNTX) has unveiled a licensing deal and collaboration with...
L&L Biopharma Completes Series B Financing for Tumor Immunotherapy Development
Shanghai-based tumor immunotherapy developer L&L Biopharma Co., Ltd has announced the completion of a Series...
Yiling Pharmaceutical’s BIO-008 Receives NMPA Approval for Clinical Trials
China-based Yiling Pharmaceutical Co., Ltd (SHE: 002603) has announced that it has received clinical trial...
Bayer’s Nubeqa Receives Additional NMPA Approval for mHSPC Treatment-Fineline Info & Tech
German pharmaceutical giant Bayer AG (ETR: BAYN) has announced that it has received another indication...
Janssen Withdraws Carvykti from UK Market Amid Manufacturing Concerns
US-based Janssen Pharmaceutical reportedly decided to withdraw Carvykti (ciltacabtagene autoleucel; cilta-cel) from the UK market...
BeiGene Declines Option for Leap Therapeutics’ DKN-01 Development Rights in Asia
US-based Leap Therapeutics Inc. (NASDAQ: LPTX) announced last week that China-based BeiGene Ltd. (HKG: 6160,...
Jacobio Pharma’s JAB-24114 Receives CDE Approval for Phase I/IIa Clinical Study
China-based Jacobio Pharma (HKG: 1167) has announced that it has received approval from the Center...
Tot Biopharmaceutical Terminates Phase III Study for HER2-Targeted ADC TAA013
Tot Biopharmaceutical International Co., Ltd (HKG: 1875) has announced the termination of the Phase III...
Shouyao Holdings Receives CDE Approval for Phase II Study of Third-Generation ALK Inhibitor
Beijing-based Shouyao Holdings (Beijing) Co., Ltd (SHA: 688197) has announced that it has received clinical...
Likang Life Sciences’ Personalized Neoantigen Vaccine LK101 Receives IND Approval
Likang Life Sciences has announced that it has received Investigational New Drug (IND) approval from...
RemeGen Gains NMPA Approval for Phase I/IIa Study of RC88 with Junshi Bio’s PD-1 Inhibitor
China-based pharmaceutical firm RemeGen (HKG: 9995) has received approval from the National Medical Products Administration...
ImmuneOnco Gains NMPA Approval for Phase Ib/II Study of IMM27M in Advanced Tumors
ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd (HKG: 1541) has announced that it has received approval from...
Henlius’ OX40 Monoclonal Antibody HLX51 Gains NMPA Approval for Phase I Clinical Study
Shanghai Henlius Biotech, Inc (HKG: 2696) has announced that it has received approval from the...
Haisco Pharmaceutical’s EGFR-PROTAC HSK40118 Gains NMPA Approval for Clinical Trials
China-based Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) has announced that it has received clinical...
Astellas Pharma’s Xtandi Gains Momentum in China with Positive Phase III ARCHES Study Results
Japan-based Astellas Pharma Inc. (TYO: 4503) has announced that its prostate cancer therapy, Xtandi (enzalutamide),...
MabPharm Files NDA for CMAB009, Biosimilar to Erbitux, Targeting Metastatic Colorectal Cancer
Taizhou-based monoclonal antibody (mAb) biosimilar specialist MabPharm Ltd (HKG: 2181) has announced the filing of...
Neowise Biotechnology Secures RMB 200 Million in Series A+ Financing Round
Neowise Biotechnology Co., Ltd, a T cell receptor (TCR)-therapy developer based in Suzhou, reportedly raised...